- Benzinga•3 days ago
DexCom, Inc. (NASDAQ: DXCM ) disclosed Friday that the FDA's panel of the Clinical Chemistry and Clinical Toxicology Devices voted in favor of its planned non-adjunctive indication for its G5 Mobile CGM ...
We keep the tough going with 2,300 convenient locations, 6,500 helpful employees & a 97% customer satisfaction rating. Talk about strength in numbers.
- The Wall Street Journal•3 days ago
DexCom Inc. shares rose Friday after a U.S. Food and Drug Administration panel voted in favor of the company’s proposed non-adjunctive indication for a glucose-monitoring system.
After hours: 87.800.00 (0.00%) as of 4:34 PM EDT
|Bid||82.84 x 100|
|Ask||94.00 x 100|
|52wk Range||47.92 - 103.29|
|Day's Range||87.02 - 87.86|
|Avg Vol (3m)||971,636|
As of 4:00 PM EDT. Market closed.